Sep. 30 at 8:29 AM
$BIO Very high affinity binding (Kₙ < 1 pM) to the TSLP receptor, allowing Verekitug to outcompete TSLP even in presence of preformed receptor complexes. In a Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP), a 100 mg dose every 12 weeks met both primary and secondary endpoints at Week 24, with generally favorable tolerability. erekitug’s receptor-targeting approach (versus ligand targeting) may deliver stronger, more durable inhibition, potentially achieving better efficacy or dosing convenience.
